Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 553-560

  Triozzi, Pierre L ^a   Shah, Jatin J ^a   Wang, Wen Quan ^a   Aldrich, Wayne ^a   Edberg, Jeffrey C ^b   Su, Kaihong ^b   Carlisle, Ronda ^a   Conry, Robert ^a   LoBuglio, Albert F ^a   Forero, Andres ^a,c  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

ADCC; GD3 monoclonal antibody; Melanoma

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; GANGLIOSIDE GD3; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOKINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KW 2871; MONOCLONAL ANTIBODY R24; RNA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG TARGETING; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MELANOMA; MONOCYTE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUPERNATANT; TUMOR GROWTH; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; GANGLIOSIDES; HUMANS; RECEPTORS, FC; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33846620496     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.553     Document Type: Article

References (26)

1. Vogel CW, Welt SW, Carswell EA, et al. A murine IgG monoclonal antibody to a melanoma antigen that activates human complement in vitro and in vivo. Immunobiology 1983;164:309.
2. Morgan AC, Graves S, Sullivan W, et al. Murine monoclonal IgG3 to human colorectal tumor associated antigens: Augmentation of antibody-dependent cell-mediated cytotoxicity (ADCC) by IL-2. Cancer Res 1989;49:2773.
3. Welt S, Carswell EA, Vogel CW, et al. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 1987;45:214.
4. Chapman PB, Yuasa H, Houghton AN. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol 1990;145:891.
5. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985;82:1242.
6. Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 1988;6:1636.
7. Ohta S, Honda A, Tokutake Y, et al. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Cancer Immunol Immunother 1993;36:260.
8. Shitara K, Kuwana Y, Nakamura K, et al. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunol Immunother 1993;36:373.
9. Scott AM, Lee FT, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KW2871 in patients with metastatic melanoma: Results of a phase I trial. J Clin Oncol 2001;19:3976.
10. Rieber EP. In: Knapp W, Dorken B, Gilks WR, et al. Leucocyte Typing IV. eds., Oxford: Oxford University, 1989:361.
11. Lunsdorf H, Kniep E, Kniep B. Immunocytochemical localization of CDw60 antigens on human peripheral T-cells. Carbohydr Res 2000;329:791.
12. Vater M, Kniep B, Gross HJ, et al. The 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B-lymphocytes. Immunol Lett 1997;59:151.
13. Ren S, Kambe N, Du Z, et al. Disialoganglioside GD3 is selectively expressed by developing and mature human mast cells. J Allergy Clin Immunol 2001;107:322.
14. Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T-lymphocytes: Evidence for a role in T-cell activation. Tissue Antigens 1990;36:47.
15. Merritt WD, Taylor BJ, Der-Minassian V, et al. Coexpression of GD3 ganglioside with CD45RO in resting and activated human T-lymphocytes. Cell Immunol 1996;173:131.
16. Norihisa Y, McVicar DW, Ghosh P, et al. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T-lymphocytes through a surface ganglioside (GD3). J Immunol 1994;152:485.
17. Welte K, Miller G, Chapman PB, et al. Stimulation of T-lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 1987;139:1763.
18. Hersey P, Schibeci SD, Townsend P, et al. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 1986;46(12 Pt 1):6083.
19. Triozzi PL, Kim J, Aldrich W. Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma. J Hematother Stem Cell Res 2003;12:279.
20. Flieger D, Spengler U, Beier I, et al. Combinations of the cytokines IL-12, IL-2, and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. Cytokine 2000;12:756.
21. Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol 1991;2:401.
22. Cebon J, MacGregor D, Scott A, et al. Immunotherapy of melanoma: Targeting defined antigens. Australas J Dermatol 1997;38(Suppl. 1):S66.
23. Schlaak JF, Claus C, Meyer zum Buschenfelde KH, et al. Anti-GD3 antibodies are potent activators of human gamma/delta and alpha/beta positive T-cells. Scand J Immunol 1995;41:475.
24. Bajorin DF, Chapman PB, Wong GY, et al. Treatment with high-dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 1992;2:355.
25. Kirkwood JM, Mascari RA, Edington HD, et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000; 88:2693.
26. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986;83:7893.